No Data
No Data
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Maintains Target Price $4
H.C. Wainwright Maintains Citius Pharmaceuticals(CTXR.US) With Buy Rating, Cuts Target Price to $4
Citius Pharmaceuticals Poised for Growth With Key Milestones and Promising Product Pipeline
Citius Pharmaceuticals Target Adjusted to $4 for Split at H.C. Wainwright
12 Health Care Stocks Moving In Tuesday's Intraday Session
Citius Pharmaceuticals Announces $2 Million Registered Direct Offering of Common Stock